Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons


Por: Dominguez, A, Castilla, J, Godoy, P, Delgado-Rodriguez, M, Saez, M, Soldevila, N, Astray, J, Mayoral, JM, Martin, V, Quintana, JM, Gonzalez-Candelas, F, Galan, JC, Tamames, S, Castro, A, Baricot, M, Garin, O, Pumarola, T, Bonfill X., López-Contreras J., Pomar V., Puig, MT, CIBERESP Cases Controls Pandemic

Publicada: 1 abr 2013
Resumen:
Background: Since influenza predisposes to bacterial pneumonia caused by Streptococcus pneumoniae, studies have suggested that pneumococcal vaccination might reduce its occurrence during pandemics. We assessed the effectiveness of pneumococcal polysaccharide vaccination alone and in combination with influenza vaccination in preventing influenza hospitalization during the 2009-2010 pandemic wave and 2010-2011 influenza epidemic. Methods: We conducted a multicenter case-control study in 36 Spanish hospitals. We selected patients aged 18 y hospitalized with confirmed influenza and two hospitalized controls per case, matched according to age, date of hospitalization and province of residence. Multivariate analysis was performed using conditional logistic regression. Subjects were considered vaccinated if they had received the pneumococcal or seasonal influenza vaccine > 14 d (or > 7 d for pandemic influenza vaccine) before the onset of symptoms (cases) or the onset of symptoms in matched cases (controls). Results: 1187 cases and 2328 controls were included. The adjusted estimate of effectiveness of pneumococcal vaccination in preventing influenza hospitalization was 41% (95% CI 8-62) in all patients and 43% (95% CI 2-78) in patients aged 65 y. The adjusted effectiveness of dual PPV23 and influenza vaccination was 81% (95% CI 65-90) in all patients and 76% (95% CI 46-90) in patients aged 65 y. The adjusted effectiveness of influenza vaccination alone was 58% (95% CI 38-72). Conclusions: In elderly people and adults with chronic illness, pneumococcal vaccination may reduce hospitalizations during the influenza season. In people vaccinated with both the influenza and pneumococcal vaccines, the benefit in hospitalizations avoided was greater than in those vaccinated only against influenza.

Filiaciones:
Dominguez, A:
 Univ Barcelona, Dept Salut Publ, Barcelona, Spain

 CIBERESP, Madrid, Spain

Castilla, J:
 CIBERESP, Madrid, Spain

 Inst Salud Publ Navarra, Pamplona, Spain

Godoy, P:
 CIBERESP, Madrid, Spain

 Generalitat Catalunya, Dept Salut, Barcelona, Spain

Delgado-Rodriguez, M:
 CIBERESP, Madrid, Spain

 Univ Jaen, Jaen, Spain

Saez, M:
 CIBERESP, Madrid, Spain

 Univ Girona, GRECS, Girona, Spain

Soldevila, N:
 CIBERESP, Madrid, Spain

Astray, J:
 Comunidad Madrid, Area Epidemiol, Madrid, Spain

Mayoral, JM:
 Serv Vigilancia Andalucia, Seville, Spain

Martin, V:
 CIBERESP, Madrid, Spain

 Univ Leon, Inst Biomed, E-24071 Leon, Spain

Quintana, JM:
 CIBERESP, Madrid, Spain

 Hosp Galdakao Usansolo, Unidad Invest, San Sebastian, Spain

Gonzalez-Candelas, F:
 CIBERESP, Madrid, Spain

 Univ Valencia, Ctr Super Invest Salud Publ, Valencia, Spain

Galan, JC:
 CIBERESP, Madrid, Spain

 Hosp Univ Ramon y Cajal, Madrid, Spain

Tamames, S:
 Junta Castilla & Leon, Direcc Gen Salud Publ & Invest, Leon, Spain

Castro, A:
 CIBER Enfermedades Resp, Madrid, Spain

Baricot, M:
 CIBERESP, Madrid, Spain

Garin, O:
 CIBERESP, Madrid, Spain

 Inst Municipal Invest Med, E-08003 Barcelona, Spain

Pumarola, T:
 REIPI, Barcelona, Spain

Bonfill X.:
 Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain

López-Contreras J.:
 Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain

Pomar V.:
 Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain

Puig, MT:
 Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain
ISSN: 21645515





Human Vaccines & Immunotherapeutics
Editorial
TAYLOR & FRANCIS INC, 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 9 Número: 4
Páginas: 865-873
WOS Id: 000327549500029
ID de PubMed: 23563516
imagen Green Published, Bronze

MÉTRICAS